Wells Fargo Is Bullish on Inspire Medical Systems, Inc. (INSP) Despite Short-Term Reimbursement Concerns

We recently compiled a list of the 15 High Growth Mid-Cap Stocks to Buy. Inspire Medical Systems, Inc. stands third on our list.

TheFly reported on January 14 that Wells Fargo lowered its price target on INSP to $145 from $160 and maintained an Overweight rating on the shares. Although Wells pointed out possible short-term inconvenience, the business stated that it is still confident in handling reimbursement issues. The complete clarification may take some time, and updates are anticipated in the Q4 call.

Separately, on January 12, Inspire Medical Systems, Inc. (NYSE:INSP) reported strong preliminary results, projecting 2026 revenue of $1.003–$1.013 billion and Q4 revenue of $268.9–$269.1 million, both above consensus expectations.

Inspire Medical Systems, Inc. (NYSE:INSP) is a U.S. medical technology company that develops and commercializes minimally invasive neurostimulation solutions for patients with moderate to severe obstructive sleep apnea. Its flagship Inspire system improves airway function and quality of life for patients who cannot tolerate CPAP therapy. The company is headquartered in Minnesota.

While we acknowledge the potential of INSP as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 12 Best Multibagger Stocks to Buy Heading into 2026 and 7 Best Rising Tech Stocks to Buy Now.

Disclosure: None.